Menu
Back to Journals » OncoTargets and Therapy » Volume 9
Original Research
Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 6,119 | Dovepress* | 5,675+ | 1,175 | 6,850 | |
| PubMed Central* | 444 | 238 | 682 | ||
| Totals | 6,119 | 1,413 | 7,532 | ||
|
*Since 30 June 2016 +Since July 2016 |
|||||
| Total mentioned | Delicious | Others | |||
|---|---|---|---|---|---|
| 3 | 0 | 0 | 0 | 1 | 2 |
View citations on PubMed and Google Scholar